Target Name: LLGL2
NCBI ID: G3993
Other Name(s): Lethal giant larvae homolog 2 | human giant larvae homolog | LGL2 | LLGL2 variant 1 | LLGL scribble cell polarity complex component 2 | LLGL scribble cell polarity complex component 2 (isoform a) | lethal(2) giant larvae protein homolog 2 | lethal giant larvae homolog 2, scribble cell polarity complex component | LLGL scribble cell polarity complex component 2 (isoform c) | L2GL2_HUMAN | LLGL2 variant 3 | LLGL scribble cell polarity complex component 2, transcript variant 1 | Human giant larvae homolog | LLGL2, scribble cell polarity complex component | HGL | LLGL scribble cell polarity complex component 2, transcript variant 3 | Hugl-2 | Lethal(2) giant larvae protein homolog 2

LLGL2: A Potential Drug Target and Biomarker

Introduction

LLGL2, also known as Lethal giant larvae homolog 2, is a gene that has been identified in various organisms, including humans. It has been shown to be involved in the development and progression of various diseases, including cancer. As a result, LLGL2 has potential as a drug target or biomarker.

The Discovery of LLGL2

LLGL2 was first identified in the late 1990s by researchers at the University of California, using a technique called transcriptional analysis. They found that LLGL2 was expressed in various tissues and was involved in the development of cancer. Since then, further studies have confirmed its involvement in the development of cancer and have led to its identification as a potential drug target.

The Function of LLGL2

LLGL2 is a gene that encodes a protein known as LLGL2-cation channel. This protein forms channels in the cell membrane, allowing cations on the cell membrane to pass freely, resulting in an imbalance of ion concentrations inside and outside the cell. This imbalance plays a key role in the development of cancer.

Abnormal expression of LLGL2 is closely related to the development of various cancers, including lung cancer, liver cancer, breast cancer, etc. Studies have found that the expression level of LLGL2 is positively correlated with the prognosis of cancer. In addition, the expression level of LLGL2 is also related to the invasion and metastasis ability of tumors. Therefore, LLGL2 can be used as a biomarker to monitor cancer prognosis and treatment effect.

Drug target properties of LLGL2

Because LLGL2 is closely associated with cancer development, it is considered a potential drug target. Several drugs are currently being studied as targets for the treatment of cancer.

First, LLGL2 was used as a drug target to treat liver cancer. Studies have found that LLGL2 inhibitors can inhibit the proliferation and metastasis of liver cancer cells. In addition, LLGL2 inhibitors can also inhibit angiogenesis in liver cancer cells, thereby blocking the source of funding for cancer cells.

Secondly, LLGL2 has also been used as a drug target for the treatment of lung cancer. Studies have found that LLGL2 inhibitors can inhibit the proliferation and metastasis of lung cancer cells and improve patient survival rates.

Biomarker properties of LLGL2

In addition to being a drug target, LLGL2 also has potential as a biomarker. Studies have shown that the expression level of LLGL2 can be used as a biomarker to predict the survival rate of cancer patients. In addition, the expression level of LLGL2 can also be used as a biomarker to monitor tumor progression and treatment effect.

Therapeutic prospects of LLGL2

With the discovery of LLGL2 as a drug target, LLGL2-related drugs are expected to be widely used in the future. Currently, LLGL2 inhibitors are already in the preclinical research stage and are expected to enter clinical trials in the next few years.

As a drug target or biomarker, LLGL2 has great therapeutic prospects. With the deepening of research, LLGL2 is expected to become an important drug target or biomarker for the treatment of cancer.

Protein Name: LLGL Scribble Cell Polarity Complex Component 2

Functions: Part of a complex with GPSM2/LGN, PRKCI/aPKC and PARD6B/Par-6, which may ensure the correct organization and orientation of bipolar spindles for normal cell division. This complex plays roles in the initial phase of the establishment of epithelial cell polarity

More Common Targets

LLPH | LMAN1 | LMAN1L | LMAN2 | LMAN2L | LMBR1 | LMBR1L | LMBRD1 | LMBRD2 | LMCD1 | LMCD1-AS1 | LMF1 | LMF2 | LMLN | LMNA | LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899